Trials
1 active
1 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Englumafusp alfa will be administered by intravenous (IV) infusion three-weekly (Q3W) in combination with a fixed dose of obinutuzumab (Part I) and in combination with a fixed dose of glofitamab (Part II and Part III).”In the company’s words, NCT04077723 on ClinicalTrials.gov
- Tested for
- Lymphoma, Non-Hodgkin
- Main trialPhase 1/2
- “This is a phase I/II, open-label, dose-escalation study designed to evaluate the safety, tolerability, and efficacy of englumafusp alfa (RO7227166) in participants with relapsed/refractory Non-Hodgkin's Lymphoma (r/r NHL). Englumafusp alfa will be administered by intravenous (IV) infusion in combination with obinutuzumab and in combination with glofitamab. A fixed dose of obinutuzumab (Gpt; pre-treatment) will be administered up to seven days prior to the first administration of englumafusp alfa and seven days prior to the first administration of glofitamab. This entry-into-human study is…”In the company’s words, NCT04077723 on ClinicalTrials.gov
Other drugs for Lymphoma, Non-Hodgkin
- GlofitamabRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- TocilizumabRoche · Phase 3
- IbrutinibJohnson & Johnson (Janssen) · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 2/3
- XNW5004Evopoint Biosciences Inc. · Phase 3
Coming up1
- 28 DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovCompletion date moved: 2027-03-31 to 2026-12-28 · ClinicalTrials.gov NCT04077723
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 28 Dec 2026 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026